ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
Stock Information for ProQR Therapeutics N.V.
Loading
Please wait while we load your information from QuoteMedia.